

Key proteins in cholesterol disorders targeted

Myriad Genetics Inc., the United States, has discovered six potential drug targets involved in the regulation of lipid metabolism. The new targets are part of the disease pathway of the Coronary Heart Disease 1 (CHD1) gene and were identified utilizing ProNet[®] – Myriad’s proprietary proteomics technology. Myriad researchers, in collaboration with Novartis, found the CHD1 gene (ZNF202). As the CHD1 gene was found to regulate multiple important components of lipid metabolism, Novartis licensed rights to CHD1 from Myriad for further therapeutic development. A better understanding of lipid metabolism may lead to a novel class of drugs that have the potential of saving lives. (Website: <http://www.bioresearchonline.com>)